AR070023A1 - Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo - Google Patents

Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo

Info

Publication number
AR070023A1
AR070023A1 ARP080103662A ARP080103662A AR070023A1 AR 070023 A1 AR070023 A1 AR 070023A1 AR P080103662 A ARP080103662 A AR P080103662A AR P080103662 A ARP080103662 A AR P080103662A AR 070023 A1 AR070023 A1 AR 070023A1
Authority
AR
Argentina
Prior art keywords
reduction
gestagens
risk
combination
endometriosis
Prior art date
Application number
ARP080103662A
Other languages
English (en)
Inventor
Konstanze Diefenbach
Kristina King
Christian Seitz
Holger Zimmermann
Annemarie Wasserfall
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR070023A1 publication Critical patent/AR070023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se usan gestágenos antiandrogénicos en una, unidad de dosis diaria que equivale a como máximo el doble de la dosis inhibidora de la ovulacion en combinacion con (6S)-5-metiltetrahidrofolato para obtener preparados farmacéuticos para la terapia de endometriosis con simultánea reduccion de los efectos colaterales terapéuticos, tales como la influencia negativa sobre la densidad osea/el metabolismo oseo y el riesgo de osteoporosis, así como, en el caso de iniciado un embarazo, la reduccion del riesgo de malformaciones congénitas, como defectos del tubo neural, fisuras palatina, de labios y mandíbula, y complicaciones en el embarazo, tales como desprendimiento de placenta y aborto, es apropiada para usar a largo plazo. Reivindicacion 3: Uso de gestágenos y (6S)-5-metiltetrahidrofolato de acuerdo con la reivindicacion 1 o 2, caracterizado porque el componente de gestágeno es 17alfa-cianometil-17-beta-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona.
ARP080103662A 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo AR070023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07016642A EP2027855A1 (de) 2007-08-24 2007-08-24 Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität

Publications (1)

Publication Number Publication Date
AR070023A1 true AR070023A1 (es) 2010-03-10

Family

ID=38846909

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103662A AR070023A1 (es) 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo

Country Status (17)

Country Link
EP (2) EP2027855A1 (es)
JP (1) JP2010536808A (es)
KR (1) KR20100047872A (es)
CN (1) CN101784271A (es)
AR (1) AR070023A1 (es)
AU (1) AU2008291406A1 (es)
BR (1) BRPI0815756A2 (es)
CA (1) CA2696030A1 (es)
CL (1) CL2008002485A1 (es)
EA (1) EA201000338A1 (es)
MX (1) MX2010002190A (es)
PA (1) PA8793901A1 (es)
PE (1) PE20090608A1 (es)
TW (1) TW200930377A (es)
UY (1) UY31306A1 (es)
WO (1) WO2009027003A1 (es)
ZA (1) ZA201002035B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN108379226B (zh) * 2018-05-28 2019-11-29 上海市计划生育科学研究所 氯地孕酮自微乳组合物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CA2316303A1 (en) 1997-12-26 1999-07-08 Masaki Nakamura Suppressing agent of angiogenesis, containing dienogest as effective ingredient
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
DE102005053771A1 (de) * 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption

Also Published As

Publication number Publication date
CL2008002485A1 (es) 2009-11-20
JP2010536808A (ja) 2010-12-02
EA201000338A1 (ru) 2010-08-30
AU2008291406A1 (en) 2009-03-05
UY31306A1 (es) 2008-11-28
EP2194978A1 (de) 2010-06-16
EP2027855A1 (de) 2009-02-25
TW200930377A (en) 2009-07-16
MX2010002190A (es) 2010-03-17
CA2696030A1 (en) 2009-03-05
CN101784271A (zh) 2010-07-21
KR20100047872A (ko) 2010-05-10
ZA201002035B (en) 2012-09-26
PA8793901A1 (es) 2009-04-23
WO2009027003A1 (de) 2009-03-05
PE20090608A1 (es) 2009-06-12
BRPI0815756A2 (pt) 2015-02-18

Similar Documents

Publication Publication Date Title
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2011003291A1 (es) Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia.
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
CO6630107A2 (es) Formas de dosificación sólidas orales con dosis muy bajas para hrt
CO6160297A2 (es) Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina
RS53876B1 (en) PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
AR070023A1 (es) Uso de gestagenos en combinacion con (6s)-5-metil-tetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
ECSP099482A (es) Preparación farmacéutica para reducir la endometriosis
PL1933843T3 (pl) Wykorzystanie walerianianu estradiolu lub estradiolu w kombinacji z dienogestem do doustnej terapii czynnościowego krwawienia macicznego w formie doustnej antykoncepcji
BR0114696A (pt) Uso de antiprogestinas para a indução de apoptose em uma célula
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
UY26966A1 (es) Uso de antiprogestinas para la inducción de apoptosis en una célula
NO20072687L (no) Farmasoytisk prevensjonspreparat
WO2008128791A3 (en) Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
CU20090116A7 (es) Preparación farmacéutica para reducir la endometriosis
UY30530A1 (es) Forma farmacologica peroral para la anticoncepcion
CO2023002874A2 (es) Nueva composición de anticonceptivo oral de liberación modificada
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas

Legal Events

Date Code Title Description
FB Suspension of granting procedure